The corticosteroid receptor hypothesis of depression

Neuropsychopharmacology

Volumn 23, Issue 5, 2000, Pages 477-501

  Holsboer, Florian ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Antidepressants; Corticosteriod receptors; CRH; Depression; HPA; Stress

Indexed keywords

ANTIDEPRESSANT AGENT; CORTICOSTEROID; CORTICOSTEROID RECEPTOR; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; HYDROCORTISONE;

CORTICOTROPIN RELEASE; DEPRESSION; GENE INACTIVATION; GENETIC PREDISPOSITION; HYDROCORTISONE RELEASE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MENTAL STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 0033797445     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(00)00159-7     Document Type: Article

References (208)

1. Alléra A., Wildt L. Glucocorticoid-recognizing and -effector sites in rat liver plasma membrane. Kinetics of corticosterone uptake by isolated membrane vesicles. I. Binding and transport. J Steroid Biochem Mol Biol. 42:1992;737-756.
2. Almeida O.F., Conde G.L., Crochemore C., Demeneix B.A., Fischer D., Hassan A.H., Meyer M., Holsboer F., Michaelidis T.M. Subtle shifts in the ratio between pro- and antiapoptotic molecules after activation of corticosteroid receptors decide neuronal fate. FASEB J. 14:2000;779-790.
3. Auphan N., Didonato J.A., Rosette C., Helmberg A., Karin M. Immunosuppression by glucocorticoids. Inhibition of NF-κB activity through induction of lκB synthesis Science. 270:1995;286-290.
4. Bale T.I., Gontarino A., Smith G.W., Chan R., Gold L.H., Sawchenko P.E., Koob G.F., Vale W.W., Lee K.-F. Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nature Genet. 24:2000;410-414.
5. Bamberger C.M., Bamberger A.M., DeCastro M., Chrousos G.P. Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans. J Clin Invest. 95:1995;2435-2441.
6. Barden N., Stec I., Montkowski A., Holsboer F., Reul J.M.H.M. Endocrine profile and neuroendocrine challenge tests in transgenic mice expressing antisense RNA against the glucocorticoid receptor. Neuroendocrinology. 66:1997;212-220.
7. Beato M., Herrlich P., Schütz G. Steroid hormone receptors. Many actors in search of a plot Cell. 83:1995;851-857.
8. Behan D.J.P., Heinrichs S.C., Troncoso J.C., Liu X.J., Kawas C.H., Ling N., De Souza E.B. Displacement of corticotropin releasing factor from its binding protein as a possible treatment for Alzheimer's disease. Nature. 378:1995;284-287.
9. Behl C., Lezoualc'h F., Trapp T., Widmann M., Skutella T., Holsboer F. Glucocorticoids enhance oxidative stress-induced cell death in hippocampal neurons in vitro. Endocrinology. 138:1997;101-106.
10. Berger S., Bleich M., Schmid W., Cole T.J., Peters J., Watanabe H.W.K., Warth R., Greger R., Schütz G. Mineralocorticoid receptor knockout mice. Pathophysiology of sodium metabolism Proc Natl Acad Sci USA. 95:1998;9424-9429.
11. Bleuler M. The Internal Secretions and the Nervous System. (Nervous and Mental Disease Monograph Series, No. 30. 1919;Nervous and Mental Disease Publ Comp, New York.
12. Brady L.S., Whitfield H.J. Jr., Fox R.J., Gold P.W., Herkenham M. Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. Therapeutic implications. J Clin Invest. 87:1991;831-837.
13. Bremner J., Southwick S., Charney D. The neurobiology of post-traumatic stress disorder. An integration of animal and human research Saigh P., Bremner J. Post-traumatic Stress Disorder. A Comprehensive Text:1999;103-143 Allyn & Cacon, Needham Heights, MA.
14. Bremner J.D., Narayan M., Anderson E.R., Staib L.H., Miller H.L., Charney D.S. Hippocampal volume reduction in major depression. Am J Psychiatry. 157:2000;115-117.
15. Burrows H.L., Nakajima M., Lesh J.S., Goosens K.A., Samuelson L.C., Inui A., Camper S.A., Seasholtz A.F. Excess corticotropin-releasing hormone-binding protein in the hypothalamic-pituitary-adrenal axis in transgenic mice. J Clin Invest. 101:1998;1439-1447.
16. Caldenhoven E., Liden J., Wissink S., Van de Stolpe A., Raaijmakers J., Okret S., Gustafsson J.-A., Van der Saag P.T. Negative crosstalk between RelA and the glucocorticoid receptor. A possible mechanism for the anti-inflammatory action of glucocorticoids Mol Endocrinol. 9:1995;401-412.
17. Calvo N., Martijena I.D., Molina V.A., Volosin M. Metyrapone pretreatment prevents the behavioral and neurochemical sequelae induced by stress. Brain Res. 800:1998;227-235.
18. Carroll J. Clinical applications of the dexamethasone suppression test for endogenous depression. Pharmacopsychiatry. 15:1982;19-24.
19. Chalmers D.T., Lovenberg T.W., De Souza E.B. Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain. Comparison with CRF1 receptor mRNA expression J Neurosci. 15:1995;6340-6350.
20. Chen G., Kolbeck R., Barde Y.-A., Bonhoeffer T., Kossel A. Relative contribution of endogenous neurotrophins in hippocampal long-term potentiation. J Neurosci. 19:1999;7983-7990.
21. Chrousos G.P., Renquist D., Brandon D., Eil C., Pugeat M., Vigersky R., Cutler G.B. Jr., Loriaux D.L., Lipsett M.B. Glucocorticoid hormone resistance during primate evolution. receptor-mediated mechanisms Proc Natl Acad Sci USA. 79:1982;2036-2040.
22. Cole T.J. Steroid receptor knockouts. Curr Opin Endocrinol Diabet. 3:1996;363-368.
23. Coplan J.D., Andrews M.W., Rosenblum L.A., Owens M.J., Friedman S., Gorman J.M., Nemeroff C.B. Persistent elevations of cerebrospinal fluid concentrations of corticotropin-releasing factor in adult non-human primates exposed to early-life stressors. Implications for the pathophysiology of mood and anxiety disorders Proc Natl Acad Sci USA. 93:1996;1619-1623.
24. Coste S.C., Kesterson R.A., Heldwein K.A., Stevens S.L., Heard A.D., Hollis J.H., Murray S.E., Hill J.K., Pantely G.A., Hohimer A.R., Hatton D.C., Phillips T.J., Finn D.A., Low M.J., Rittenberg M.B., Stenzel P., Stenzel-Poore M.P. Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2. Nature Genet. 24:2000;403-409.
25. de Bellis M.D., Gold P.W., Geracioti T.D. Jr., Listwak S.J., Kling M.A. Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression. Am J Psychiatry. 150:1993;656-657.
26. de Kloet E.R., Vreugdenhil E., Oitzl M.S., Joëls M. Brain corticosteroid receptor balance in health and disease. Endocrinol Rev. 19:1998;269-301.
27. de Kloet E.R., Oitzl M.S., Joëls M. Stress and cognition. Are corticosteroids good or bad guys? Trends Neurosci. 22:1999;422-426.
28. de Quervain D.J.-F., Roozendaal B., McGaugh J.L. Stress and glucocorticoids impair retrieval of long-term spatial memory. Nature. 394:1998;787-790.
29. Deguchi M., Yoshiaki I., Matsukawa S., Yamaguchi A., Nakagawara G. Useful of metyrapone treatment to suppress cancer metastasis facilitated by surgical stress. Surgery. 123:1998;440-449.
30. Delgado P.L., Charney D.S., Price L.H., Aghajanian G.K., Landis H., Heninger G.R. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan Arch Gen Psychiatry. 47:1990;411-418.
31. Delgado P.L., Price L.H., Heninger G.R., Charney D.S. Neurochemistry of affective disorders. Paykel E.S. Handbook of Affective Disorders. 1992;219-253 Churchill Livingstone, New York, NY.
32. Detera-Wadleigh S.D., Berrettini W.H., Goldin L.R., Martinez M., Hsieh W.T., Hoehe M.R., Encio I.J., Coffman D., Rollins D.Y., Muniec D. A systematic search for a bipolar predisposing locus on chromosome 5. Neuropsychopharmacology. 6:1992;219-229.
33. Dijkstra I., Tilders F.J.H., Aguilera G., Kiss A., Rabandan-Diehl C., Barden N., Karanth S., Holsboer F., Reul J.M.H.M. Reduced activity of hypothalamic corticotropin-releasing hormone neurons in transgenic mice with impaired glucocorticoid receptor function. J Neurosci. 18:1998;3909-3918.
34. Dodt C., Kern W., Fehm H.L., Born J. Antimineralocorticoid canrenoate enhances secretory activity of the hypothalamus-pituitary-adrenocortical (HPA) axis in humans. Neuroendocrinology. 58:1993;570-574.
35. Drouin J., Sun Y.L., Chamberland M., Gauthier Y., De Lean A., Nemer M., Schmidt T.J. Novel glucocorticoid receptor complex with DNA element of the hormone-repressed POMC gene. EMBO J. 12:1993;145-156.
36. Drouin J., Maira M., Philips A. Novel mechanism of action for Nur77 and antagonism by glucocorticoids. A convergent mechanism for CRH activation and glucocorticoid repression of POMC gene transcription J Steroid Biochem Mol Biol. 65:1998;59-63.
37. Duman R.S., Heninger G.R., Nestler E.J. A molecular and cellular theory of depression. Arch Gen Psychiatry. 54:1997;597-606.
38. Eiring A., Sulser F. An increased synaptic availability of norepinephrine is not essential for antidepressant induced increases in hippocampal GR mRNA. J Neural Transm. 104:1997;1255-1258.
39. Erkut Z.A., Pool C., Swaab D.F. Glucocorticoids suppress corticotropin-releasing hormone and vasopessin expression in human hypothalamic neurons. J Clin Endocrinol Metab. 83:1998;2066-2073.
40. Flood J.F., Morley J.E., Roberts E. Pregnenolone sulfate enhances post-training memory processes when injected in very low doses into limbic system structures; the amygdala is by far the most sensitive. Proc Natl Acad Sci USA. 92:1995;10806-10810.
41. Freedman L.P. Increasing the complexity of coactivation in nuclear receptor signaling. Cell. 97:1999;5-8.
42. Gold P.W., Loriaux D.L., Roy A., Kling M.A., Calabrese J.R., Kellner C.H., Nieman L.K., Post R.M., Pickar D., Gallucci W., Avgerinos P., Paul S., Oldfield E.H., Cutler G.B. Jr., Chrousos G.P. Responses to corticotropin-releasing hormone in the hypoercortisolism of depression and Cushing's disease. N Engl J Med. 314:1986;1329-1335.
43. Gould E., McEwen B.S., Tanapat P., Galea L.A.M., Fuchs E. Neurogenesis in the dentate gyrus of the adult tree shrew is regulated by psychosocial stress and NMDA receptor activation. J Neurosci. 17:1997;2492-2498.
44. Gray T.S., Bingaman E.W. The amygdala. Corticotropin-releasing factor, steroids, and stress Critical Rev Neurobiol. 10:1996;155-168.
45. Greden F., Gardner R., King D., Grunhaus L., Carroll J., Kronfol Z. Dexamethasone suppression test in antidepressant treatment of melancholia. Arch Gen Psychiatry. 40:1983;493-500.
46. Hassan A.H.S., von Rosenstiel P., Patchev V.K., Holsboer F., Almeida O.F.X. Exacerbation of apoptosis in the dentate gyrus of the aged rat by dexamethasone and the protective role of corticosterone. Exp Neurol. 140:1996;43-52.
47. Hassan A.H.S., Patchev V.K., von Rosenstiel P., Holsboer F., Almeida O.F.X. Plasticity of hippocampal corticosteroid receptors during aging in the rat. FASEB J. 13:1999;115-122.
48. Healy D.G., Harkin A., Cryan J.F., Kelly J.P., Leonard B.E. Metyrapone displays antidepressant-like properties in preclinical paradigms. Psychopharmacology. 145:1999;303-308.
49. Heck S., Kullmann M., Gast A., Ponta H., Rahmsdorf H.J., Herrlich P., Cato A.C.B. A distinct modulating domain in glucocorticoid receptor monomers in the repression of activity of the transcription factor AP-1. EMBO J. 13:1994;4087-4095.
50. Heim C., Newport D.J., Heit S., Graham Y.P., Wilcox M., Bonsall R., Miller A.H., Nemeroff C.B. Increased pituitary-adrenal and autonomic responses to stress in adult women after sexual and physical abuse in childhood. JAMA. In press:2000.
51. Heinrichs S.C., Lapsansky J., Lovenberg T.W., De Souza E.B., Chalmers D.T. Corticotropin-releasing factor CRF1, but not CRF2 receptors mediate anxiogenic-like behavior. Regul Peptides. 71:1997;15-21.
52. Heuser I., Yassouridis A., Holsboer F. The combined dexamethasone/CRH test. A refined laboratory test for psychiatric disorders J Psychiatric Res. 28:1994;341-356.
53. Heuser I.J.E., Schweiger U., Gotthardt U., Schmider J., Lammers C.H., Dettling M., Yassouridis A., Holsboer F. Pituitary-adrenal-system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and in normal comparison subjects. Am J Psychiatry. 153:1996;93-99.
54. Holsboer F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J Psychiatric Res. 33:1999;181-214.
55. Holsboer F., Barden N. Antidepressants and HPA regulation. Endocrinol Rev. 17:1996;187-203.
56. Holsboer F., Liebl R., Hofschuster E. Repeated dexamethasone suppression test during depressive illness. Normalization of test result compared with clinical improvement. J Affect Disord. 4:1982;93-101.
57. Holsboer F., Gerken A., Von Bardeleben U., Grimm W., Beyer H., Müller O.A., Stalla G.K. Human corticotropin-releasing hormone (CRH) in patients with depression, alcoholism and panic disorder. Biol Psychiatry. 21:1986;601-611.
58. Holsboer F., Von Bardeleben U., Wiedemann K., Müller O.A., Stalla G.K. Serial assessment of corticotropin-releasing hormone response after dexamethasone in depression - implications for pathophysiology of DST nonsuppression. Biol Psychiatry. 22:1987;228-234.
59. Holsboer F., Spengler D., Heuser I. The role of corticotropin-releasing hormone in the pathogenesis of Cushing's disease, anorexia nervosa, alcoholism, affective disorders and dementia. Prog Brain Res. 93:1992;385-417.
60. Holsboer F., Lauer C.J., Schreiber W., Krieg J.-C. Altered hypothalamic-pituitary-adrenocortical regulation in healthy subjects at high familial risk for affective disorders. Neuroendocrinology. 62:1995;340-347.
61. Holsboer-Trachsler E., Hemmeter U., Hatzinger M., Seifritz E., Gerhard U., Hobi V. Sleep deprivation and bright light as potential augmenters of antidepressant drug treatment - neurobiological and psychometric assessment of course. J Psychiatric Res. 28:1994;381-399.
62. Hope B.T., Nye H.E., Kelz M.B., Self D.W., Iadarola M.J., Nakabeppu Y., Duman R.S., Nestler E.J. Induction of a long-lasting AP-1 complex composed of altered Fos-like proteins in brain by chronic cocaine and other chronic treatments. Neuron. 13:1994;1235-1244.
63. Huizenga N.A.T.M., Koper J.W., de Lange P., Pols H.A.P., de Jong F.H., Stolk R.P., Grobbee D.E., Lamberts S.W.J. Interperson variability, but intraperson reproducibililty of baseline cortisol concentrations and its relation to the feedback sensitivity of the hypothalamo-pituitary-adrenal axis to low dose dexamethasone. J Clin Endocrinol Metab. 83:1998;47-54.
64. Joëls M., de Kloet E.R. Control of neuronal excitability by corticosteroid hormones. Trends Neurosci. 15:1992;25-30.
65. Kafitz K.W., Rose C.R., Thoenen H., Konnerth A. Neurotrophin-evoked rapid excitation through TrkB receptors. Nature. 401:1999;918-921.
66. Kanelakis K.C., Morishima Y., Dittmar K.D., Galigniana M.D., Takayama S., Reed J.C., Pratt W.B. Differential effects of the hsp70-binding protein BAG-1 on glucocorticoid receptor folding by the hsp90-based chaperone machinery. J Biol Chem. 274:1999;34134-34140.
67. Kang K.I., Meng X., Devin-Leclerc J., Bouhouche I., Chadli A., Cadepond F., Baulieu E.-E., Catelli M.-G. The molecular chaperone hsp90 can negatively regulate the activity of a glucocorticosteroid-dependent promoter. Proc Natl Acad Sci USA. 96:1999;1439-1444.
68. Karanth S., Linthorst A.C.E., Stalla G.K., Barden N., Holsboer F., Reul J.M.H.M. Hypothalamic-pituitary-adrenocortical axis changes in a transgenic mouse with impaired glucocorticoid receptor function. Endocrinology. 138:1997;3476-3485.
69. Karolyi I.J., Burrows H.L., Ramesh T.M., Nakajima M., Lesh J.S., Seong E., Camper S.A., Seasholtz A.F. Altered anxiety and weight gain in corticotropin-releasing hormone-binding protein-deficient mice. Proc Natl Acad Sci USA. 96:1999;11595-11600.
70. Kendler K.S., Karkowski L.M., Prescott C.A. Causal relationship between stressful life events and the onset of major depression. Am J Psychiatry. 156:1999;837-841.
71. Kerr D.S., Campell L.W., Applegate M.D., Brodish A., Landfield P.W. Chronic stress-induced acceleration of electrophysiologic and morphometric biomarkers of hippocampal aging. J Neurosci. 11:1991;1316-1324.
72. Kishimoto T., Radulovic J., Radulovic M., Lin C.R., Schrick C., Hooshmand F., Hermanson O., Rosenfeld M.G., Spiess J. Deletion of Crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2. Nature Genet. 24:2000;415-419.
73. Koper J.W., Stolk R.P., de Lange P., Huizenga N.A.T.M., Molijn G.-J., Pols H.A.P., Grobbee D.E., Karl M., de Jong F.H., Brinkmann A.O., Lamberts S.W.J. Lack of association between five polymorphisms in the human glucocorticoid receptor gene and glucocorticoid resistance. Human Genet. 99:1997;663-668.
74. Korte M., Carroll P., Wolff E., Brem G., Thoenen H., Bonhoeffer T. Hippocampal long-term potentiation is impaired in mice lacking brain-derived neurotrophic factor. Proc Natl Acad Sci USA. 92:1995;8856-8860.
75. Korte M., Griesbeck O., Gravel C., Carroll P., Staiger V., Thoenen H., Bonhoeffer T. Virus-mediated gene transfer into hippocampal CA1 region restores long-term potentiation in brain-derived neurotrophic factor mutant mice. Proc Natl Acad Sci USA. 93:1996;12547-12552.
76. Lackner C., Daufeldt S., Wildt L., Alléra A. Glucocorticoid-recognizing and -effector sites in rat liver plasma membrane. Kinetics of corticosterone uptake by isolated membrane vesicles. III. Specificity and stereospecificity. J Steroid Biochem Mol Biol. 64:1998;69-82.
77. Ladd C.O., Owens M.J., Nemeroff C.B. Persistent changes in corticotropin-releasing factor neuronal systems induced by maternal deprivation. Endocrinology. 137:1996;1212-1218.
78. Lamberts S.W.J., Koper J.W., Biemond P., den Holder F.H., de Jong F.H. Cortisol receptor resistance. The variability of its clinical presentation and response to treatment J Clin Endocrinol Metab. 74:1992;313-321.
79. Lamberts S.W.J., Huizenga A.T.M., de Lange P., de Jong F.H., Koper J.W. Clinical aspects of glucocorticoid sensitivity. Steroids. 61:1996;157-160.
80. Landfield P.W., Baskin R.K., Pitler T.A. Brain aging correlates. Retardation by hormonal-pharmacological treatments Science. 214:1981;581-584.
81. Lanz R.B., McKenna N.J., Onate S.A., Albrecht U., Wong J., Tsai S.Y., Tsai M.-J., O'Malley B.W. A steroid receptor coactivator, SRA, functions as an RNA and is present in an SRC-1 complex. Cell. 97:1999;17-274.
82. Lauer C.J., Schreiber W., Modell S., Holsboer F., Krieg J.-C. The Munich vulnerability study of affective disorders. J Psychiatric Res. 32:1998;393-401.
83. Legradi G., Holzer D., Kapcala L.P., Lechan R.M. Glucocorticoids inhibit stress-induced phosphorylation of CREB in corticotropin-releasing hormone neurons of the hypothalamic paraventricular nucleus. Neuroendocrinology. 66:1997;86-97.
84. Leverenz J.B., Wilkinson C.W., Wamble M., Corbin S., Grabber J.E., Raskind M.A., Peskind E.R. Effect of chronic high-dose exogenous cortisol on hippocampal neuronal number in aged nonhuman primates. J Neurosci. 19:1999;2356-2361.
85. Levine S., Mullins R.F. Hormonal influences on brain organization in infant rats. Science. 152:1966;1585-1592.
86. 1 receptor antisense oligodeoxynucleotide into the central nucleus of the amygdala reduced anxiety-related behavior in socially defeated rats. Regul Peptides. 59:1995;229-239.
87. 2 receptor antisense oligodeoxynucleotides into the rat brain. J Psychiatric Res. 33:1999;153-163.
88. Linthorst A.C.E., Flachskamm C., Hopkins S.J., Hoadley M.E., Labeur M.S., Holsboer F., Reul J.M.H.M. Long-term intracerebroventricular infusion of corticotropin-releasing hormone alters neuroendocrine, neurochemical, autonomic, behavioral, and cytokine responses to a systemic inflammatory challenge. J. Neurosci. 17:1997;4448-4460.
89. Linthorst A.C.E., Karanth S., Barden N., Holsboer F., Reul J.M.H.M. Impaired glucocorticoid receptor function evolves in aberrant physiological responses to bacterial endotoxin. Eur J Neurosci. 11:1999;178-186.
90. Linthorst A.C.E., Flachskamm C., Barden N., Holsboer F., Reul J.M.H.M. Glucocorticoid receptor impairment alters CNS responses to a psychological stressor. An in vitro microdialysis study in transgenic mice Eur J Neurosci. 12:2000;283-291.
91. Liu J., DeFranco D.B. Chromatin recycling of glucocorticoid receptors. Implications for multiple roles of heat shock protein 90 Mol Endocrinol. 13:1999;355-365.
92. Lôo H., Saiz-Ruiz J., Costa e Silva J.A., Ansseau M., Herrington R., Vaz-Serra A., Dilling H., de Risio S. Efficacy and safety of tianeptine in the treatment of depressive disorders in comparison with fluoxetine. J Affect Disord. 56:1999;109-118.
93. Lupien S.J., de Leon M., de Santi S., Convit A., Tarshish C., Nair N.P.V., Thakur M., McEwen B.S., Hauger R.L., Meaney M.J. Cortisol levels during human aging predict hippocampal atrophy and memory deficits. Nature Neurosci. 1:1998;69-73.
94. Magariños A.M., McEwen B.S., Flügge G., Fuchs E. Chronic psychosocial stress causes apical dendritic atrophy of hippocampal CA3 pyramidal neurons in subordinate tree shrews. J Neurosci. 16:1996;3534-3540.
95. Magariños A.M., Verdugo J.M., McEwen B.S. Chronic stress alters synaptic terminal structure in hippocampus. Proc Natl Acad Sci USA. 94:1997;14002-14008.
96. Malkoski S.M., Handanos C.M., Dron R.I. Localization of a negative glucocorticoid response element of the human corticotropin releasing hormone gene. Mol Cell Endocrinol. 127:1997;189-199.
97. Malkoski S.P., Dorin R.I. Composite glucocorticoid regulation at a functionally defined negative glucocorticoid response element of the human corticotropin-releasing hormone gene. Mol Endocrinol. 13:1999;1629-1644.
98. Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schütz G., Umesono K., Blumberg B., Kastner P., Mark M., Chambon P., Evans R.M. The nuclear receptor superfamily. The second decade Cell. 83:1995;835-839.
99. McEwen B.S., Angulo J., Cameron H., Chao H.M., Daniels D., Gannon M.N., Gould E., Mendelson S., Sakai R., Spencer R., Woolley C. Paradoxical effects of adrenal steroids on the brain. Protection versus degeneration Biol Psychiatry. 31:1992;177-199.
100. Meijer O.C., Cole T.J., Schmid W., Schütz G., Joëls M., De Kloet E.R. Regulation of hippocampal 5-HT1A receptor mRNA and binding in transgenic mice with a targeted disruption of the glucocorticoid receptor. Mol Brain Res. 46:1997;290-296.
101. Meijer O.C., de Lange E.C.M., Breimer D.D., de Boer A.G., Workel J.O., De Kloet E.R. Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1AP-glycoprotein knockout mice. Endocrinology. 139:1998;1789-1793.
102. Modell S., Yassouridis A., Huber J., Holsboer F. Corticosteroid receptor function is decreased in depressed patients. Neuroendocrinology. 65:1997;216-222.
103. Modell S., Lauer C.J., Schreiber W., Huber J., Krieg J.-C., Holsboer F. Hormonal response pattern in the combined DEX-CRH test is stable over time in subjects at high familial risk for affective disorders. Neuropsychopharmacology. 18:1998;253-262.
104. Montkowski A., Barden N., Wotjak C., Stec I., Ganster J., Meaney M., Engelmann M., Reul J.M.H.M., Landgraf R., Holsboer F. Long-term antidepressant treatment reduces behavioural deficits in transgenic mice with impaired glucocorticoid receptor function. J Neuroendocrinol. 7:1995;841-845.
105. Morissette J., Villeneuve A., Lordeleau L., Rochette D., Laberge C., Gagné B., Laprise C., Bouchard G., Plante M., Gobeil L., Shink E., Weissenbach J., Barden N. Genome-wide search for linkage of bipolar affective disorders in a very large pedigree derived from a homogeneous population in Quebec points to a locus of major effect on chromosome 12q23-q24. Am J Med Genet. 88:1999;567-587.
106. Müller M.B., Lucassen P.J., Yassouridis A., Hoogendijk W.J.G., Holsboer F., Swaab D.E. The human hippocampus in major depression or following administration of glucocorticoids. No evidence for major structural alterations Soc Neurosci Abstr. 24:1998;990.
107. Murphy B.E.P. Treatment of major depression with steroid suppressive drugs. J Steroid Biochem Mol Biol. 39:1991;239-244.
108. Murphy B.E.P., Filipini D., Ghadirian A.M. Possible use of glucocorticoid receptor antagonists in the treatment of major depression. Preliminary results using RU 486 J Psychiatry Neurosci. 18:1993;209-213.
109. Murphy E.P., Conneely O.M. Neuroendocrine regulation of the hypothalamic pituitary adrenal axis by the nurr1/nur77 subfamily of nuclear receptors. Mol Endocrinology. 11:1997;39-47.
110. Nelson M.D., Saykin A.J., Flashman L.A., Riordan H.J. Hippocampal volume reduction in schizophrenia as assessed by magnetic resonance imaging. A meta-analytic study. Arch Gen Psychiatry. 55:1998;433-440.
111. Nemeroff C.B., Widerlov E., Bissette G., Walleus H., Karlsson I., Eklund K., Kilts D.C., Loosen P.T., Vale W. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science. 226:1984;1342-1344.
112. Nemeroff C.B., Owens M.J., Bissette G., Andorn A.C., Stanley M. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch Gen Psychiatry. 45:1988;377-379.
113. Newcomer J.W., Selke G., Melson A.K., Hershey T., Craft S., Richards K., Alderson A.L. Decreased memory performance in healthy humans induced by stress-level cortisol treatment. Arch Gen Psychiatry. 56:1999;527-533.
114. Nollen E.A.A., Brunsting J.F., Song J., Kampinga H.H., Morimoto R.I. Bag1 functions in vivo as a negative regulator of hsp70 chaperone activity. Mol Cell Biol. 20:2000;1083-1088.
115. O'Dwyer A.M., Lightman S.L., Marks M., Checkley S.A. Treatment of major depression with metyrapone and hydrocortisone. J Affect Disord. 33:1995;123-128.
116. Oitzl M.S., Fluttert M., De Kloet E.R. The effect of corticosterone on reacitivity to spatial novelty is mediated by central mineralocorticosteroid receptors. Eur J Neurosci. 6:1994;1072-1079.
117. Orchinik M., Murrey T.F., Moore F.L. A corticosteroid receptor in neuronal membranes. Science. 252:1991;1848-1851.
118. Owens M.J., Nemeroff C.B. Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev. 43:1991;425-473.
119. Pariante C.M., Pearce B.D., Pisell T.L., Owens M.J., Miller A.H. Steroid-independent translocation of the glucocorticoid receptor by the antidepressant desipramine. Mol Pharmacol. 52:1997;571-581.
120. Patchev V.K., Shoaib M., Holsboer F., Almeida O.F.X. The neurosteroid tetrahydroprogesterone counteracts corticotropin-releasing hormone-induced anxiety and alters the release and gene expression of corticotropin-releasing hormone in the rat hypothalamus. Neuroscience. 62:1994;265-271.
121. Patchev V.K., Hassan A.H.S., Holsboer F., Almeida O.F.X. The neurosteroid tetrahydroprogesterone attenuates the endocrine response to stress and exerts glucocorticoid-like effects on vasopressin gene transcription in the rat hypothalamus. Neuropsychopharmacology. 15:1996;533-540.
122. Patchev V.K., Montkowski A., Rouskova D., Koranyi L., Holsboer F., Almeida O.F.X. Neonatal treatment of rats with the neuroactive steroid tetrahydrodeoxycorticosterone (THDOC) abolishes the behavioral and neuroendocrine consequences of adverse early life events. J Clin Invest. 99:1997;962-966.
123. Paul S.M., Purdy R.H. Neuroactive steroids. FASEB J. 6:1992;2311-2322.
124. Pepin M.C., Pothier F., Barden N. Impaired type II glucocorticoid-receptor function in mice bearing antisense RNA transgene. Nature. 355:1992;725-728.
125. Pfahl M. Nuclear receptor/AP-1 interaction. Endocrinol Rev. 14:1993;651-658.
126. Philips A., Maira M., Mullick A., Chamberland M., Lesage S., Hugo P., Drouin J. Antagonism between Nur77 and glucocorticoid receptor for control of transcription. Mol Cell Biol. 17:1997;5952-5959.
127. Plotsky P., Meaney M. Early, postnatal experience alters hypothalamic corticotropin-releasing factor (CRF) mRNA, median eminence CRF-content and stress-induced release in adult rats. Mol Brain Res. 18:1993;195-200.
128. Potter E., Behan D.P., Fischer W.H., Linton E.A., Lowry P.J., Vale W.W. Cloning and characterization of the cDNAs for human and rat corticotropin releasing factor-binding proteins. Nature. 349:1991;423-426.
129. Pratt W.B., Dittmar K.D. Studies with purified chaperones advance the understanding of the mechanism of glucocorticoid receptor-hsp90 heterocomplex assembly. TEM. 9:1998;244-252.
130. Purba J.S., Hoogendijk W.J.G., Hofman M.A., Swaab D.F. Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. Arch Gen Psychiatry. 53:1996;137-143.
131. Raadsheer F.C., Hoogendijk W.J.G., Stam F.C., Tilders F.H.J., Swaab D.F. Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology. 60:1994;433-436.
132. Radulovic J., Rühmann A., Liepold T., Spiess J. Modulation of learning and anxiety by corticotropin-releasing factor (CRF) and stress. Differential roles of CRF receptors 1 and 2 J Neurosci. 19:1999;5016-5025.
133. Rajkowska G., Miguel-Hidalgo J.J., Wei J., Dilley G., Pittman S.D., Meltzer H.Y., Overholser J.C., Roth B.L., Stockmeier C.A. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry. 45:1999;1085-1098.
134. Reichardt H.M., Kaestner K.H., Tuckermann J., Kretz O., Wessely O., Bock R., Gass P., Schmid W., Herrlich P., Angel P., Schütz G. DNA binding of the glucocorticoid receptor is not essential for survival. Cell. 93:1998;531-541.
135. Reynolds P.D., Ruan Y., Smith D.F., Scammell J.G. Glucocorticoid resistance in the squirrel monkeys is associated with overexpression of the immunophilin FKBP51. J Clin Endocrinol Metab. 84:1999;663-669.
136. Reul J.M.H.M., Stec I., Söder M., Holsboer F. Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system. Endocrinology. 133:1993;312-320.
137. Reul J.M.H.M., Labeur M.S., Grigoriadis D.E., De Souza E.B., Holsboer F. Hypothalamic-pituitary-adrenocortical axis changes in the rat after long-term treatment with the reversible monoamine oxidase-A inhibitor moclobemide. Neuroendocrinology. 60:1994;509-519.
138. Reul J.M.H.M., Probst J.C., Skutella T., Hirschmann M., Stec I.S., Montkowski A., Landgraf R., Holsboer F. Increased stress-induced adrenocorticotropin response after long-term intracerebroventricular treatment of rats with antisense mineralocorticoid receptor oligodeoxynucleotides. Neuroendocrinology. 65:1997;189-199.
139. Rochford J., Beaulieu S., Rousse I., Glowa J., Barden N. Behavioral reactivity to aversive stimuli in a transgenic mouse model of impaired glucocorticoid (type II) receptor function. Effects of diazepam and FG-7142 Psychopharmacology. 132:1997;145-152.
140. Romeo E., Ströhle A., Spalletta G., di Michele F., Hermann B., Holsboer F., Pasini A., Rupprecht R. Effects of antidepressant treatment on neuroactive steroids in major depression. Am J Psychiatry. 155:1998;910-913.
141. Roozendaal B., Nguyen B.T., Power A.E., McGaugh J.L. Basolateral amygdala noradrenergic influence enables enhancement of memory consolidation induced by hippocampal glucocorticoid receptor activation. Proc Natl Acad Sci USA. 96:1999;11642-11647.
142. Rossby S.P., Nalepa I., Huang M., Burt A., Perrin C., Schmidt D.E., Sulser F. Norepinephrine-independent regulation of GRII mRNA in vivo by a tricyclic antidepressant. Brain Res. 687:1995;79-82.
143. Rossby S.P., Manier D.H., Liang S., Nalepa I., Sulser F. Pharmacological actions of the antidepressant venlafaxine beyond aminergic receptors. Intl J Neuropsychopharmacol. 2:1999;1-8.
144. Rousse I., Beaulieu S., Rowe W., Meaney M.J., Barden N., Rochford J. Spatial memory in transgenic mice with impaired glucocorticoid receptor function. NeuroReport. 8:1997;841-845.
145. Rubin R.T., Poland R.E., Lesser I.M., Winston R.A., Blodgett A.L.N. Neuroendocrine aspects of primary endogenous depression. Arch Gen Psychiatry. 44:1987;328-336.
146. Rupprecht R., Holsboer F. Neuroactive steroids. Mechanisms of action and neuropsychopharmacological perspectives Trends Neurosci. 22:1999;410-416.
147. Rupprecht R., Reul J.M.H.M., Trapp T., van Steensel B., Wetzel C., Zieglgänsberger W., Damm K., Holsboer F. Progesterone receptor mediated effects of neuroactive steroids. Neuron. 11:1993;523-530.
148. Rybakowski J.K., Twardowska K. The dexamethasone/corticotropin-releasing hormone test in depression in bipolar and unipolar affective illness. J Psychiatric Res. 33:1999;363-370.
149. Sánchez M.M., Young L.J., Plotsky P.M., Insel T.R. Autoradiographic and in situ hybridization localization of corticotropin-releasing factor 1 and 2 receptors in nonhuman primate brain. J Comp Neurol. 408:1999;365-377.
150. Sánchez M.M., Young L.J., Plotsky P.M., Insel T.R. Distribution of corticosteroid receptors in the rhesus brain. Relative absence of glucocorticoid receptors in the hippocampal formation J Neuroscience. 20:2000;4657-4668.
151. Sapolsky R.M. Stress, the Aging Brain and the Mechanism of Neuron Death. 1992;MIT Press, London.
152. Schatzberg A.F., Rothschild A.J., Langlais P.J., Bird E.D., Cole J.O. A corticosteroid/dopamine hypothesis for psychotic depression and related states. J Psychiatric Res. 19:1985;57-64.
153. Schinkel A.H., Wagenaar E., Van Deemter L., Mol C.A.A.M., Borst P. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest. 96:1995;1698-1705.
154. Schneikert J., Hübner S., Martin E., Cato A.C.B. A nuclear action of the eukaryotic cochaperone RAP46 in downregulation of glucocorticoid receptor activity. J Cell Biol. 146:1999;929-940.
155. Schulkin J., Gold P.W., McEwen B.S. Induction of corticotropin-releasing hormone gene expression by glucocorticoids. Implication for understanding the states of fear and anxiety and allostatic load Psychoneuroendocrinology. 23:1998;219-243.
156. Schwaninger M., Schoel C., Blume R., Rossig L., Knepel W. Inhibition by antidepressant drugs of cyclic AMP response element-binding protein/cyclic AMP response element-directed gene transcription. Mol Pharmacol. 47:1995;1112-1118.
157. Seasholtz A.F., Thompson R.C., Douglass J.O. Identification of a cyclic adenosine monophosphate-responsive element in the rat corticotropin-releasing hormone gene. Mol Endocrinol. 2:1988;1311-1319.
158. Seckl J.R. 11β-Hydroxysteroid dehydrogenase in the brain. A neural regulator of glucocorticoid action? Front Neuroendocrinol. 18:1997;49-99.
159. Seckl J.R., Fink G. Antidepressants increase glucocorticoid and mineralocorticoid receptor mRNA expression in rat hippocampus in vivo. Neuroendocrinology. 55:1992;621-626.
160. Seckl J.R., Dickson K.L., Yates C., Fink G. Distribution of glucocorticoid and mineralocorticoid receptor messenger RNA expression in human postmortem hippocampus. Brain Res. 561:1991;332-337.
161. Sheline Y.I., Wang P.W., Gado M.H., Hsernansky J.G., Vannier M.W. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci USA. 93:1996;3908-3913.
162. Sheline Y.I., Gado M., Price J.L. Amygdala core nuclei volumes are decreased in recurrent major depression. NeuroReport. 9:1998;2023-2028.
163. Sheline Y.I., Sanghavi M., Mintun M.A., Gado M.H. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci. 19:1999;5034-5043.
164. Shelton R.C., Manier D.H., Peterson C.S., Truitt C.E., Sulser F. Cyclic AMP-dependent protein kinase in subtypes of major depression and normal volunteers. Intl J Neuropsychopharmacol. 2:1999;187-192.
165. Shibata H., Spencer T.E., Onate S.A., Jenster G., Tsai S.Y., Tsai M.-J., O'Malley B.W. Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. Rec Progr Hormone Res. 52:1997;141-163.
166. Sillaber I., Montkowski A., Landgraf R., Barden N., Holsboer F., Spanagel R. Enhanced morphine-induced behavioural effects and dopamine release in the nucleus accumbens in a transgenic mouse model of impaired glucocorticoid (type II) receptor function. Influence of long-term treatment with the antidepressant moclobemide Neuroscience. 85:1998;415-425.
167. Siuciak J.A., Lewis D., Wiegand S.J., Lindsay R.M. Antidepressant-like effect of brain-derived neurotrophic factor. Pharmacol Biochem Behav. 56:1996;131-137.
168. Skutella T., Probst J.C., Renner R., Holsboer F., Behl C. Corticotropin-releasing hormone receptor (type I) antisense targeting reduces anxiety. Neuroscience. 85:1998;795-805.
169. Smith G.W., Aubry J.-M., Dellu F., Contarino A., Bilezikjian L.M., Gold L.H., Hauser C., Bentley C.A., Sawchenko P.E., Koob G.F., Vale W., Lee K.-F. Corticotropin-releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron. 20:1998;1093-1103.
170. Sonntag A., Rothe B., Guldner J., Yassouridis A., Holsboer F., Steiger A. Trimipramine and imipramine exert different effects on the sleep EEG and on nocturnal hormone secretion during treatment of major depression. Depression. 4:1996;1-13.
171. Spanagel R., Stöhr T., Barden N., Holsboer F. Morphine-induced locomotor and neurochemical stimulation is enhanced in transgenic mice with impaired glucocorticoid receptor function. J Neuroendocrinol. 8:1996;93-97.
172. Spencer R.L., Kim P.J., Kalman B.A., Cole M.A. Evidence for mineralocorticoid receptor facilitation of glucocorticoid receptor-dependent regulation of hypothalamic-pituitary-adrenal axis activity. Endocrinology. 139:1998;2718-2726.
173. Spencer T.E., Jenster G., Burcin M.M., Allis C.D., Zhou J., Mizzen C.A., McKenna N.J., Onate S.A., Tsai S.Y., Tsai M.-J., O'Malley B.W. Steroid receptor coactivator-1 is a histone acetyltransferase. Nature. 389:1997;194-198.
174. Spengler D., Rupprecht R., Phi Van L., Holsboer F. Identification and characterization of a 3',5'-cyclic adenosine monophosphate-responsive element in the human corticotropin-releasing hormone gene promoter. Mol Endocrinol. 6:1992;1931-1941.
175. Stalla G.K., Stalla J., von Werder K. Nitroimidazole derivates inhibit anterior pituitary cell function apparently by a direct effect on the catalytic subunit of the adenylate cyclase holoenzyme. Endocrinology. 155:1989;699-706.
176. Stec I., Barden N., Reul J.M.H.M., Holsboer F. Dexamethasone nonsuppression in transgenic mice expressing antisense RNA to the glucocorticoid receptor. J Psychiatric Res. 28:1994;1-5.
177. Steckler T., Weis C., Sauvage M., Mederer A., Holsboer F. Disrupted allocentric but preserved egocentric spatial learning in transgenic mice with impaired glucocorticoid receptor function. Behav Brain Res. 100:1999;77-89.
178. Steckler T., Sauvage M., Holsboer F. Glucocorticoid receptor impairment enhances impulsive responding in transgenic mice performing on a simultaneous visual discrimination task. Eur J Neuroscience. In press:2000;. a.
179. Steckler T., Rammes G., Sauvage M., van Gaalen M.M., Weis C., Zieglgänsberger W., Holsboer F. Effects of the monoamine oxidase A inhibitor moclobemide on hippocampal plasticity in GR-impaired transgenic mice. J Psychiatric Res. In press:2000;. b.
180. Stenzel-Poore M.P., Heinrichs S.C., Rivest S., Koob G.F., Vale W.W. Overproduction of corticotropin-releasing factor in transgenic mice. A genetic model of anxiogenic behavior J Neurosci. 14:1994;2579-2584.
181. Stoecklin E., Wissler M., Gouilleux F., Groner B. Functional interactions between Stat5 and the glucocorticoid receptor. Nature. 383:1996;726-728.
182. Stoecklin E., Wissler M., Moriggl R., Groner B. Specific DNA binding of Stat5, but not of glucocorticoid receptor, is required for their functional co-operation in the regulation of gene transcription. Mol Cell Biol. 17:1997;6708-6716.
183. Ströhle A., Poettig M., Barden N., Holsboer F., Montkowski A. Age- and stimulus-dependent changes in anxiety-related behaviour of transgenic mice with GR dysfunction. NeuroReport. 9:1998;2099-2102.
184. Ströhle A., Pasini A., Romeo E., Hermann B., Spalletta G., di Michele F., Holsboer F., Rupprecht R. Fluoxetine decreases concentrations of 3α,5α-tetrahydrodeoxycorticosterone (THDOC) in major depression. J Psychiatric Res. 34:2000;183-186.
185. Swanson L.W., Simmons D.M. Differential steroid hormones and neural influences on peptide mRNA levels in CRH cells of the paraventricular nucleus. A hybridization histochemical study in the rat J Comp Neurol. 285:1989;413-435.
186. Thakore J.H., Dinan T.G. Cortisol synthesis inhibition. A new treatment strategy for the clinical and endocrine manifestations of depression Biol Psychiatry. 37:1995;364-368.
187. Timpl P., Spanagel R., Sillaber I., Kresse A., Reul J.M.H.M., Stalla G.K., Blanquet V., Steckler T., Holsboer F., Wurst W. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nature Genet. 19:1998;162-166.
188. Trapp T., Rupprecht R., Castrèn M., Reul J.M.H.M., Holsboer F. Heterodimerization between mineralocorticoid and glucocorticoid receptor. A new principle of glucocorticoid action in the CNS Neuron. 13:1994;1457-1462.
189. Trapp T., Holsboer F. Heterodimerization between mineralocorticoid and glucocorticoid receptor increases the functional diversity of corticosteroid action. Trends in Pharmacol Sci. 17:1996;145-149. a.
190. Trapp T., Holsboer F. Nuclear orphan receptor as a repressor of glucocorticoid receptor transcriptional activity. J Biol Chem. 271:1996;9879-9882. b.
191. Tronche R., Kellendonk C., Kretz O., Gass P., Anlag K., Orban P.C., Bock R., Klein R., Schütz G. Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety. Nature Genet. 23:1999;99-103.
192. Uhr M., Steckler T., Yassouridis A., Holsboer F. Penetration of amitriptyline, but not fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology. 22:2000;380-387.
193. Uzunova V., Sheline Y., Davis J.M., Rasmusson A., Uzunov D.P., Costa E., Guidotti A. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci USA. 95:1998;3239-3244.
194. Vale W., Spiess J., Rivier C., Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and β-endorphin. Science. 213:1981;1394-1397.
195. van der Burg B., Liden J., Okret S., Delaunay F., Wissink S., van der Saag P.T., Gustafsson J.-A. Nuclear factor-κB repression in antiinflammation and immunosuppression by glucocorticoids. Trends Endocrinol Metab. 8:1997;152-157.
196. van Haarst A.D., Welberg L.A.M., Sutanto W., Oitzl M.S., De Kloet E.R. 11β-Hydroxysteroid dehydroxygenase activity in the hippocampus. Implications for in vivo corticosterone receptor binding and cell nuclear retention J Neuroendocrinol. 8:1996;595-600. a.
197. van Haarst A.D., Oitzl M.S., Workel J.O., De Kloet E.R. Chronic brain glucocorticoid receptor blockade enhances the rise in circadian and stress-induced pituitary-adrenal activity. Endocrinology. 137:1996;4935-4943. b.
198. von Bardeleben U., Holsboer F. Cortisol response to a combined dexamethasone-hCRH challenge in patients with depression. J Neuroendocrinol. 1:1989;485-488.
199. von Bardeleben U., Holsboer F. Effect of age upon the cortisol response to human CRH in depressed patients pretreated with dexamethasone. Biol Psychiatry. 29:1991;1042-1050.
200. von Bardeleben U., Holsboer F., Stalla G.K., Müller O.A. Combined administration of human corticotropin-releasing factor and lysine vasopressin induces cortisol escape from dexamethasone suppression in healthy subjects. Life Sci. 37:1985;1613-1619.
201. Watanabe Y., Gould E., McEwen B.S. Stress induces atrophy of spatial dendrites of hippocampal CA3 pyramidal neurons. Brain Res. 588:1992;341-345.
202. Weninger S.C., Dunn A.J., Muglia L.J., Dikkes P., Miczek K.A., Swiergiel A.H., Berridge C.W., Majzoub J.A. Stress-induced behaviors require the corticotropin-releasing hormone (CRH) receptor, but not CRH. Proc Natl Acad Sci USA. 96:1999;8283-8288.
203. Wissink S., van Heerde E.C., van der Burg B., van der Saag P.T. A dual mechanism mediates repression of NF-κB activity by glucocorticoids. Mol Endocrinol. 12:1998;355-363.
204. Wolkowitz O.M., Reus V.I., Chan T., Manfredi F., Raum W., Johnson R., Canick J. Antiglucocorticoid treatment of depression. Double-blind ketoconazole Biol Psychiatry. 45:1999;1070-1074.
205. Young E.A., Lopez J.F., Murphy-Weinberg V., Watson S.J., Akil H. The role of mineralocorticoid receptors in hypothalamic-pituitary-adrenal axis regulation in humans. J Clin Endocrinol Metab. 83:1998;3339-3345.
206. Zeiner M., Niyaz Y., Gehring U. The hsp70-associating protein Hap46 binds to DNA and stimulates transcription. Proc Natl Acad Sci USA. 96:1999;10194-10199.
207. Zobel A.W., Yassouridis A., Frieboes R.-M., Holsboer F. Cortisol response to the combined dexamethasone-CRH test predicts medium-term outcome in patients with remitted depression. Am J Psychiatry. 156:1999;949-951.
208. Zobel A.W., Nickel T., Künzel H.E., Ackl N., Sonntag A., Ising M., Holsboer F. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression. The first 20 patients treated J Psychiatric Res. 34:2000;171-181.